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Background: The presentation of a leukemoid reaction in cervical cancers is rare. A leukemoid reaction is defined
as leukocytosis associated with a cause outside the bone marrow, with the white blood cell count (WBC) exceeding
50*109/L. Two cervical cancers presenting with leukemoid reactions were previously reported. However, the cancers
in these cases were mainly in the advanced stages and had a poor outcome.
Case presentation: Here we report a 40-year old patient with clinical stage (FIGO IIA1) cervical squamous carcinoma
suffering from vaginal cuff recurrence with a leukemoid reaction two months after laparoscopic radical hysterectomy.
The patient suffered from persistent fever and leukocytosis after one month of antibiotic treatment accompanied by
rapid growth of the vaginal mass indicated that the leukocytosis could not be caused only by infection. After paclitaxel
injection, the WBC count increased to 70.37*109/L. Bone marrow aspirates and biopsy showed left-shift neutrophilia,
which confirmed leukemoid reaction. After two courses of paclitaxel and cisplatin treatment, the white blood cell
counts decreased to normal, the fever disappeared, and the vaginal mass was reduced dramatically. She achieved
completed remission after subsequent chemo-radiation and two additional courses of chemotherapy.
Conclusion: In our case, leukemoid reaction was related to recurrent cervical carcinoma and sensitive to chemotherapy.
To our knowledge, this is the third case to be reported in the literature. Furthermore, this is the only case described that
shows an unequivocal correlation between tumor response and leukemoid reaction.
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Cervical cancer is the third most common cancer and
the fourth leading cause of cancer death in women
worldwide, and more than 85% of cases occur in devel-
oping countries [1]. Clinically, the primary treatment for
early stage cervical cancer is surgery, radiation therapy,
or concurrent chemoradiation. The 5-year survival rate
for early stage cervical cancer is 70% [2].
A white blood cell count (WBC) exceeding 50*109/L
associated with a cause outside the bone marrow is
termed a leukemoid reaction (LR). LR is generally be-
nign, although it could resemble more serious conditions
that are medical dilemmas. Its frequency in patients with
nonhematologic cancers remains unclear, although it has* Correspondence: jingsakura@gmail.com
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LR has been reported in nearly all solid tumor types as a
paraneoplastic syndrome and is historically associated
with poor outcome. Cervical cancers presenting with LR
are rarely reported. Only two authors, Nimieri [3] and Kyo
[4], have reported LR in cervical cancer patients. However,
the cancers in these cases were mainly in advanced stage.
Here, we report a patient with relatively early stage (Inter-
national Federation of Gynecology and Obstetrics, FIGO
IIA1) cervical squamous carcinoma suffering from recur-
rence with LR two months after laparoscopic radical hys-
terectomy. The clinical and histological features are




A 40-year-old woman who was experiencing increased
discharge and postcoital bleeding for 2 months was
admitted to the Obstetrics and Gynecology Hospital ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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stump was found via bimanual examination, and tissue
biopsy results verified that it was infiltrative cervical
squamous carcinoma. Magnetic resonance imaging
(MRI) examination indicated a 2.7*2.2*3.4 cm lesion in
the posterior cervix, accompanied by disappearance of
the posterior fornix. (Figure 1A) Preoperative examina-
tions, including a routine blood test (WBC: 5.93*109/L,
neutrophils: 58%, lymphocytes: 33%, monocytes: 6%, eo-
sinophils: 2%), analysis of tumor markers (squamous cell
cancer antigen, SCCA: 0.7 ng/mL; CA125: 14.32 U/L), and
determination of the leukocyte alkaline phosphate score
(LAP: 145 U/L), produced normal results (Figure 2). Be-
cause the patient was diagnosed with Federation of Gynae-
cology and Obstetrics (FIGO) IIA1 cervical cancer, she
underwent surgery (laparoscopic radical hysterectomy,
pelvic lymphadenectomy, vaginoplasty, and ovarian trans-
position) on April 24, 2012. A pathological examination
revealed a 3 cm non-keratinized squamous carcinoma lo-
cated in 3°-9° of the cervix, with distances of 1.5 cm up to
internal orifice and 0.5 cm down to the fornix. The tumor
was confined to the inner half of the cervical stroma; lym-
phovascular invasion and pelvic lymph node metastasis
were not detected. Immunohistochemical staining showed
positivity for p16 (+++), p53 (+), and Ki-67 (90%+), and
CD31 and D240 staining confirmed that the vessels were
intact (Figure 3). Because the patient had no risk factors
for adjuvant therapy, she was dismissed from the hospital
7 days after the operation.
On July 2, 2012 (68 days after the operation), she pre-
sented to the outpatient clinic with increasing discharge.
A 2*3 cm swollen cystic area was found in the posterior
vagina. As purulent cells were found in her vaginal dis-
charge, she was diagnosed with vaginitis and prescribedFigure 1 Magnetic resonance imaging of primary and recurrent cervica
cervix, accompanied by disappearance of the posterior fornix. B. The arrow inornidazole to control the infection. On July 16, 2012,
due to a high fever of 39.2°C and urine retention, she
went to the urological outpatient clinic to receive
catheterization. With a white blood cell count of 23*109/L,
she was diagnosed with a urinary tract infection and re-
ceived intravenous cefotiam and levofloxacin. However,
her fever was not well controlled. On July 30, 2012,
a 60 mm diameter solid mass on the posterior vagina
with an ulcerous surface was found by gynecological
examination. MRI scan confirmed a homogeneous solid
68*63*58 mm mass located in the space between the
bladder and the rectum (Figures 1B and 4). MRI well
displayed the tumor itself and its margin. After injection
of contrast materials, the relationship between the
tumor and surrounding tissues also was well appreci-
ated on serial MRI scans. Hydronephrosis of both kid-
neys and distension of upper region of the left ureter
were confirmed by ultrasonic inspection. Biopsy was
performed on the mass, which demonstrated degener-
ated squamous cells within necrotic tissue.
She was admitted to the inpatient ward again on August 2.
2012. Because of an uncontrollable fever (range: 39–40.5°C)
and leukocytosis (WBC: 29.66*109/L), samples of her
blood, urine, and vaginal discharge were taken for bacter-
ial culture to identify the source of infection. The cultures
were all negative on August 2, 2012; however, Escherichia
Colli, ESBLs (extended-spectrum β-Lactamase) sensitive
to tienam and amikacin were found in a vaginal bacterial
culture on August 5, 2012. Repeated discharge culture on
August 12, 2012 was negative and became ESBLs positive
again on August 17, 2012, then turned to negative on
August 29, 2012. Since admission, empiric therapy with
ceftriaxone sodium and metronidazole had been used;
however, this was subsequently changed to a combinationl mass. A. The arrow indicated a 2.7*2.2*3.4 cm lesion in the posterior
dicated a 68*63*58 mm mass in the vaginal cuff.
Figure 2 Dynamic changes in tumor volume (the maximum diameter of tumor), tumor markers (SCCA and CA125), white blood cell
(WBC) counts, and LAP response to chemotherapy. Upper panel: The levels of CA125 and SCCA were correlated with the tumor volume.
The WBC counts remained at a high level since recurrence and reached its highest value after the first round of chemotherapy. Bottom panel:
The levels of LAP, neutrophils, lymphocytes, and monocytes were in accordance with the WBC counts.
Figure 3 HE and immunohistochemical (Ki-67, CD31, P53) staining of primary (A, B, C, D) and relapsed (E, F, G, H) cancer tissues.
H&E staining (A) showed irregular nests of squamous cell carcinoma dispersed in the stroma, with various quantities of inflammatory cells
infiltrating the stromal tissues as well as cancerous nests. In the relapsed cancer tissue (E), neutrophils were more predominant, whereas in
primary cancer tissues, a mixed population of lymphocytes and neutrophils was observed. The immunohistochemical staining patterns of Ki-67
(B, F), CD31 (C, G), and p53 (D, H) were similar in the primary and relapsed tissue. Ki-67 positively expressed in >90% of tumor cells. P53 was
strongly expressed in tumor cells.
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test on Aug 5, 2012. From August 12, 2012 to August 24,
2012, the patient was treated with norvancomycin and
cefoperazone-sulbactam and subsequently with piperacillin-
tazobactam plus amikacin for an additional 7 days.
On the other hand, although a biopsy on July 30, 2012
showed no malignancy (the possible negative result
might be attributed to superficial biopsy sample), the re-
currence of cervical carcinoma was highly suspected be-
cause the vaginal mass increased from 22*33*22 mm on
July 2, 2012 to 63*65*58 mm on July 30, 2012 and the
characteristics showed by MRI highly suggested a recur-
rent tumor. The tumor mass increased to 80 mm in
diameter by palpation on August 6, 2012. A second
bulky biopsy was performed on August 7, 2012. In order
to get enough tissue, we cut the surface open, and ex-
cised a 60*40*20 mm mass. The whole mass was solid
without abscess. After the biopsy, the tumor volume
shrank to 70*40*40 mm. Pathology examination con-
firmed recurrent squamous carcinoma. Immunochemis-
try staining for Ki-67 and P53 was also performed
(Figure 3). Chemotherapy was considered but was post-
poned because the patient was recently given sensitive an-
tibiotics (tienam and vancomycin) and effective control of
fever and leukocytosis was expected. However, one week
later, the high fever (up to 39.2°C) and leukocytosis (up to
33.4*109/L) were persistent. In addition, the mass contin-
ued growing to 90*82*74 mm on August 14, 2012 and
tumor makers became abnormal (CA125: 76.66 U/L,
SCCA: 5.3 ng/ml). Considering the severity of the situ-
ation, we decided to give the patient a new regimen of an-
tibiotics and chemotherapy simultaneously.
Regarding chemotherapy, paclitaxel (200 mg) was ad-
ministered intravenously on August 15, 2012. Unexpect-
edly, on the following day, her fever increased (40.3°C),
and the planned cisplatin treatment was cancelled. On
August 21, 2012, cisplatin (100 mg) was injected because
the patient had become relatively stable (fever, 39°C;
WBC, 18.95*109/L). On August 25, 2012, her WBC count
reached 70.37*109/L, and a leukemoid reaction (LR) was
suspected. Bone marrow aspirates and biopsy showed an
increased myeloid/erythroid ratio, active myeloid prolifer-
ation, and normal megakaryocytopoiesis. Meanwhile, her
LAP level was extremely high (869 U/L). Considering the
lab tests, the diagnosis of LR was established. On August
28, 2012 (12 days after paclitaxel and 1 week after cisplatin
injection), her WBC count was reduced to 39.23*109/L,
the mass was reduced to 65*46*40 mm, and SCCA and
CA125 had decreased to 1.0 ng/ml and 49.46 U/L, re-
spectively. On September 4, 2012 (three weeks after pacli-
taxel treatment), her fever and WBC count decreased to
normal levels (36.8°C and 8.1*109/L). Subsequently, the
levels of tumor markers returned to normal. The second
course of paclitaxel (210 mg) and cisplatin (120 mg) wasadministered on September 10, 2012 and the vaginal mass
was successfully eliminated on September 17, 2012. Add-
itionally, after chemotherapy was performed, ultrasound
results indicated that the kidney and IVP were normal.
The dynamic changes in WBC, LAP, tumor makers, and
tumor volume along with the chemotherapy are illustrated
in Figure 2.
From October 10, 2012 to November 16, 2012, the pa-
tient received external irradiation to a dose of 45 Gy in
25 fractions with concurrent cisplatin chemotherapy. No
abnormality was observed on MRI on November 19,
2012. After radiotherapy, she was treated with chemo-
therapy (100 mg docetaxel together with 300 mg carbo-
platin) on December 17, 2012 and January 14, 2013. The
follow-up was satisfying: her WBC, CA125, and SCCA
levels were normal. The latest follow-up on May 23,
2014 showed no evidence of recurrence.
Discussion
Data analysis
As depicted in Figure 2, the basal WBC level increased
from 5.93*109/L preoperatively to 29.66*109/L at 99 days
after the operation. A high fever with a sharp increase in
WBC indicated infection. However, the infection was
not severe as it was superficial. Persistent fever and
leukocytosis after one month of antibiotic treatment ac-
companied by rapid growth of the vaginal mass indi-
cated that the leukocytosis could not be caused only by
infection. In addition, the characteristics on MRI find-
ings such as homogeneous isointensity signal on T2WI
and hyper-intensity signal compared with hypointensity
signal of background on DWI highly suggested recurrent
tumor (Figure 4). Furthermore, during the second
biopsy, the mass was solid but containing no abscess at
all. Last, after paclitaxel injection, the WBC count in-
creased to 70.37*109/L. Bone marrow aspirates and bi-
opsy showed left-shift neutrophilia, which confirmed LR
and excluded chronic myelogenous leukemia (CML).
LAP detection was consistent with the trend in WBC
counts. Three weeks after the first course of paclitaxel
and cisplatin treatment, the levels of CA125, SCCA, and
WBC decreased to normal, the fever disappeared, and
the vaginal mass was reduced dramatically. SCCA, de-
fined as squamous cell carcinoma antigen, one of the
most popular diagnostic tumor markers of cervical can-
cer, has a sensitivity of 67-100% and specificity of 90-
96% in recurrent cervical squamous cervical cancer. The
elevation of SCCA could also be occurred in psoriasis,
eczema, and severe kidney disease. In our case, SCCA
was elevated with the recurrence and subsequently de-
creased after chemotherapy, which was in accordance
with tumor burden. Thus, in our case, LR was related to
recurrent cervical carcinoma and sensitive to chemo-
therapy. The LR was distinguished from CML directly
Figure 4 MRI scans for the recurrent tumor. (A) Axial fat-suppressed T2WI; (B) Sagittal fat-suppressed T2WI; (C) Diffusion weighted imaging
(DWI); (D) Contrast-enhanced fat-suppressed T1WI. In this case, the giant oval mass (arrowhead) with homogeneous isointensity signal was
well demonstrated on T2WI (A, B). Note, the balloon catheter (arrow) was placed into the bladder. On DWI (C), the tumor (arrowhead) appears
hyper-intensity signal compared with hypointensity signal of background. On contrast-enhanced MRI (D), the tumor mildly enhanced and the necrosis
component (*) did not enhanced. Note, the mass-rectum margin was not clear (arrow), indicating the tumor invaded the anterior wall of rectum.
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between tumor response and leukocytosis as well as an
increased LAP [5].
The possible cause of LR in cancer patients
As in many other carcinomas, we considered LR as a para-
neoplastic syndrome associated with cancer and attributed
to increased cytokine production. Fever is an integral
component of leukemoid reaction resulting from either
release of endogenous pyrogens or due to necrotic-
inflammatory phenomena of the tumor. Various studies
have reported elevations in granulocyte colony-stimulating
factor (G-CSF), granulocyte-macrophage colony-stimulating
factor (GM-CSF), and interleukin-6 (IL-6) in tumors of
the cervix, pancreatic cancer, hepatocellular carcinoma,
and lung cancer [4,6-8]. Animal experiments have demon-
strated that interleukin-6 (IL-6) can sustain neutrophil/
macrophage colonies in vivo and that, through its action
on other immune cells, it can induce the production of
several CSFs by the bone marrow [9]. Despite stimulating
bone marrow to sustain leukocytosis, IL-3, GM-CSF,
and G-CSF have been shown to stimulate the growth of
clonogenic cells of some nonhematopoietic malignant cell
lines in vitro [5]. Hurtado et al. found that when G-CSF
was overproduced by tumor cells, it had a tendency toencourage the development of myeloid-derived suppressor
cells (MDSC), which could travel to lymph nodes to pre-
vent dendritic cell-primed T lymphocytes from eliminat-
ing tumor cells [10]. Therefore, consistent with the clinical
presentation of our case, paraneoplastic granulocytosis is
often associated with rapid tumor growth and poor clin-
ical prognosis, although it resolves with the treatment of
the underlying cancers. Especially when infection is not
likely or not the only contributor, the possibility of tumor
origin should be considered when patients present with an
LR of unknown etiology. Nevertheless, drugs that induce
LRs, such as methotrexate [11] and carbamazepine [12],
should be avoided.
The pathological characteristics of cancers with LR
Although we did not measure the G-CSF, GM-CSF, or
IL-6 in the tumor cells, we compared the HE sections
and several immunochemical markers in primary and
recurrent tumors to investigate the possible factors re-
lated to the unusual presentation in our case. Based on
Figure 2, there were more neutrophils in the tissue after
the recurrence than before the recurrence, although the
primary lesion had more neutrophils than usual. The in-
filtration of the tumor by neutrophil granulocytes and
lymphocytes proved to be significant for prognosis and
Table 1 Pathoclinical features in three cases of cervical cancer with LR
Case* Author Year Age Stage Previous treatment Time to
recurrence
Recurrence site Pathology WBC (*10^9/L) Treatment Survival
1 Satoru [4] 2000 56 IB2 Radical hysterectomy, bilateral
salpingo-oophorectomy, and
pelvic lymphadenectomy
15 days Right parametrial space SCC# 58 Not mentioned 68 days after
surgery, DOD$
2 Nimieri [3] 2003 81 IVB Chemotherapy and local radiotherapy N/A SCC 93 Chemotherapy, local
radiotherapy
6 weeks, DOD
3 Current report 2013 40 IIA1 laparoscopic radical hysterectomy,
pelvic lymphadenectomy, vaginoplasty,
and ovarian transposition
68 days Vaginal SCC 70 Chemotherapy + radiation 20 months, Alive
*: A patient of cervical cancer with LR was mentioned in Granger and Kontoyiannis’s review article [14]. However, no information in detail was provided. Thus, this case was not included in Table 1.
#: SCC: Squamous cell carcinoma.
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lymphocytes in a cancerous lesion may be a clue indicat-
ing the potential for rapid recurrence. Nevertheless, Carus
et al. recently assessed tumor-associated CD66b(+) neu-
trophils and CD163(+) macrophages by immunohisto-
chemistry in whole tissue sections of 101 FIGO IB and IIA
cervical cancer patients and found tumor-associated neu-
trophil count was an independent prognostic factor for
short recurrence free survival in localised cervical cancer
[14]. The Ki-67 index, a marker of cell proliferation, is
similarly associated with tumor recurrence and prognosis.
A 90% positive Ki-67 score in a primary lesion might be
an indicator of rapid recurrence. P53, which is often asso-
ciated with poor prognosis, was also remarkably positively
expressed in primary and recurrent tumors.
Treatment strategies for patients with LR
Treatment strategies for cancer with LR are limited and
are rarely reported in the literature. As Granger and
Kontoyiannis reported in a retrospective, single-institution
study, patients who survived longer than 1 year received
effective antineoplastic therapy, chemotherapy, or surgery.
However, these authors did not mention specific strategies
[15]. The majority of malignant tumors with LR respond
poorly to chemotherapy, and the patients die shortly after.
For example, a lung cancer patient with LR treated with
various drugs, including vinorelbine, cisplatin, docetaxel,
pemetrexed, and gemcitabine died two weeks after starting
third-line therapy [16]. In our case, we used paclitaxel
combined with cisplatin to control the development of LR.
Surprisingly, after two courses of chemotherapy, the very
large recurrent tumor completely disappeared and the
WBC count decreased to normal. Subsequently, the pa-
tient received concurrent chemo-radiation therapy and an
additional two courses of docetaxel combined with carbo-
platin. The patient survived for longer than 20 months
after recurrence.
Prognosis of tumor patients with LR
Patients with LR always have a poor prognosis with
a tumor burden and a poor condition. Granger and
Kontoyiannis [15] analyzed the etiology and outcome of
extreme leukocytosis in 758 nonhematologic cancer pa-
tients, including 4 gynecological cancers, 1 of which was
cervical cancer. Patients diagnosed with an LR typically
had neutrophil predominance (96%), radiographic evi-
dence of metastatic disease (78%), and a poor prognosis.
In total, 78% of the patients either died or were dis-
charged to hospice within 12 weeks of their initial ex-
treme leukocyte count. Ma drew a similar conclusion in
malignant bone tumor patients [17]. In a comprehensive
review of inflammatory malignant fibrous histiocytoma
(IMFH) associated with LR or leukocytosis, the severity
of LR was correlated with the time of death. Once theWBC reached 100*109/L, the patients were not capable
of tolerating any chemoradiation secondary to their un-
stable clinical condition [10]. Mabuchi also concluded
that pretreatment leukocytosis was an independent
prognostic factor in patients with cervical cancer [18]. In
comparison with other two cases of cervical cancer with
LR in the literature, despite the severe condition (high
fever and rapid growth of the tumor), our patient toler-
ated and responded to chemotherapy, and eventually
achieved complete remission (Table 1).
Conclusion
To our knowledge, this is the first case report of an early
stage cervical cancer suffering rapid recurrence with leu-
kemoid reaction achieving a good prognosis due to early
diagnosis and timely chemotherapy. Unusual infiltration
of the tumor by neutrophil granulocytes and high ex-
pression of Ki-67 and P53 may relate to rapid recurrence
and leukemoid reaction.
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